Mastitis, metritis, agalactia (MMA)

*<p>p<0.05 comparing trend across each CD4 count category within an age category.</p>¶<p>p<0.01 comparing trend across each CD4 count category within an age category.</p

Factors associated with higher levels of cardiovascular risk.

<p>Age is a categorical variable defined by three age categories: 16–35, 36–45 and <45 years.</p><p>CD4 count is a binary variable: ≥200 and <200 cells/mm³.</p><p>BMI was not included as a covariate in the risk factor analysis because BMI≥25 kg/m² is one of the cardiovascular risk factors.</p>*<p>HTN: hypertension.</p

Factors associated with higher levels of cardiovascular risk among patients using protease inhibitors.

<p>Age is a categorical variable defined by three age categories: 16–35, 36–45 and <45 years.</p><p>CD4 count is a binary variable: ≥200 and <200 cells/mm³.</p><p>BMI was not included as a covariate in the risk factor analysis because BMI≥25 kg/m² is one of the cardiovascular risk factors.</p>*<p>HTN: hypertension.</p

Summary of Clinical Characteristics.

<p><b><u>BP</u></b>: blood pressure. <b><u>BMI</u></b><u>:</u> body mass index. <b><u>eGFR</u></b>: estimated glomerular filtration rate. <b><u>CKD</u></b>: chronic kidney disease. <b><u>PI</u></b>: protease inhibitor. <b><u>ART:</u></b> anti-retroviral therapy.</p>§<p>The sample size was smaller for males (n = 1,471) and females (n = 2,494).</p>???<p>The sample size was smaller for males (n = 3,078) and females (n = 4,932).</p><p>*<b><u>Prehypertension</u></b> is defined as SBP 120–139 mmHg or DBP 80–89 mmHg.</p>¶<p><b><u>Hypertension</u></b> is defined as SBP≥140 mmHg or DBP≥90 mmHg. Use of anti-hypertensive medications was not routinely assessed. <b><u>Overweight/Obese</u></b> is defined as BMI≥25 kg/m².</p>±<p>Based on the following factors: SBP≥140 mmHg, DBP≥90 mmHg and BMI≥25 kg/m².</p

Comparison of outcomes of atrial fibrillation patients.

<p>Comparison of outcomes of atrial fibrillation patients.</p

Flow diagram of enrollment and12-months follow-up.

<p>Legend. AF = atrial fibrillation, LTFU = lost to follow up.</p

Medication use before study entry for atrial fibrillation patients.

<p>Medication use before study entry for atrial fibrillation patients.</p

Baseline characteristics of atrial fibrillation patients.

<p>Baseline characteristics of atrial fibrillation patients.</p